Enhancing longevity of immunoisolated pancreatic islet grafts by modifying both the intracapsular and extracapsular environment

Qin, Tian; Smink, Alexandra M.; Vos, Paul de

doi:10.1016/j.actbio.2023.06.038

Cited by 12 publications

(8 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, cell encapsulation technology plays a crucial role in islet transplantation. ViaCyte, Inc. is the most advanced in cell therapy encapsulation, with a multilayer design that uses a semipermeable polytetrafluoroethylene membrane and an external polyester mesh to protect implanted cells ( 104 ). PEC-01 is a therapy that involves directing human embryonic stem cells to differentiate into pancreatic endoderm cells ( 105 ).…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous device-free islet transplantation

Zhou,

Xu,

You

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Diabetes mellitus is a chronic metabolic disease, characterized by high blood sugar levels; it affects more than 500 million individuals worldwide. Type 1 diabetes mellitus (T1DM) is results from insufficient insulin secretion by islets; its treatment requires lifelong use of insulin injections, which leads to a large economic burden on patients. Islet transplantation may be a promising effective treatment for T1DM. Clinically, this process currently involves directly infusing islet cells into the hepatic portal vein; however, transplantation at this site often elicits immediate blood-mediated inflammatory and acute immune responses. Subcutaneous islet transplantation is an attractive alternative to islet transplantation because it is simpler, demonstrates lower surgical complication risks, and enables graft monitoring and removal. In this article, we review the current methods of subcutaneous device-free islet transplantation. Recent subcutaneous islet transplantation techniques with high success rate have involved the use of bioengineering technology and biomaterial cotransplantation—including cell and cell growth factor co-transplantation and hydrogel– or simulated extracellular matrix–wrapped subcutaneous co-transplantation. In general, current subcutaneous device-free islet transplantation modalities can simplify the surgical process and improve the posttransplantation graft survival rate, thus aiding effective T1DM management.

show abstract

Section: Discussionmentioning

confidence: 99%

Subcutaneous device-free islet transplantation

Zhou,

Xu,

You

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…This could significantly address the issue of donor shortage for transplantation. Additionally, new approaches for immunoisolation have demonstrated successes of up to a year of insulin independence in experimental animals [ 7 ], providing hope for immunosuppressive-free transplantation of islets.…”

Section: Introductionmentioning

confidence: 99%

“…To obtain long-term functioning immunoisolated islet grafts, it is essential to make modifications both on the outside and inside of the capsules [ 7 ]. Examples of modifications on the outside of capsules include the adherence of antifibrotic factors or immunomodulating molecules such as pectins [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Pancreatic stellate cells support human pancreatic β-cell viability in vitro and enhance survival of immunoisolated human islets exposed to cytokines

Qin,

Hu,

Kong

et al. 2024

Materials Today Bio

Self Cite

View full text Add to dashboard Cite

“…In this immediate period after transplantation, islets are very susceptible to inflammation in the vicinity of the graft, which might be induced by the mandatory implantation surgery or by danger‐associated molecular patterns (DAMPs) released from the islets 8,9 . During this acute period, islets are rebuilding their extracellular matrix, adapting to their new microenvironment, and are vulnerable to stress 10 . Many insulin‐producing cells die in this immediate period after transplantation by several cell death processes including necroptosis.…”

Section: Introductionmentioning

confidence: 99%

“…8,9 During this acute period, islets are rebuilding their extracellular matrix, adapting to their new microenvironment, and are vulnerable to stress. 10 Many insulin-producing cells die in this immediate period after transplantation by several cell death processes including necroptosis.…”

mentioning

confidence: 99%

Necrostatin‐1 releasing nanoparticles: In vitro and in vivo efficacy for supporting immunoisolated islet transplantation outcomes

Smink,

Medina,

de Haan

et al. 2023

J Biomedical Materials Res

Self Cite

View full text Add to dashboard Cite

Immunoisolation of pancreatic islets in alginate microcapsules allows for transplantation in the absence of immunosuppression but graft survival time is still limited. This limited graft survival is caused by a combination of tissue responses to the encapsulating biomaterial and islets. A significant loss of islet cells occurs in the immediate period after transplantation and is caused by a high susceptibility of islet cells to inflammatory stress during this period. Here we investigated whether necrostatin‐1 (Nec‐1), a necroptosis inhibitor, can reduce the loss of islet cells under stress in vitro and in vivo. To this end, we developed a Nec‐1 controlled‐release system using poly (D,L‐lactide‐co‐glycolide) (PLGA) nanoparticles (NPs) as the application of Nec‐1 in vivo is limited by low stability and possible side effects. The PLGA NPs stably released Nec‐1 for 6 days in vitro and protected beta cells against hypoxia‐induced cell death in vitro. Treatment with these Nec‐1 NPs at days 0, 6, and 12 post‐islet transplantation in streptozotocin‐diabetic mice confirmed the absence of side effects as graft survival was similar in encapsulated islet grafts in the absence and presence of Nec‐1. However, we found no further prolongation of graft survival of encapsulated grafts which might be explained by the high biocompatibility of the alginate encapsulation system that provoked a very mild tissue response. We expect that the Nec‐1‐releasing NPs could find application to immunoisolation systems that elicit stronger inflammatory responses, such as macrodevices and vasculogenic biomaterials.

show abstract

Enhancing longevity of immunoisolated pancreatic islet grafts by modifying both the intracapsular and extracapsular environment

Cited by 12 publications

References 180 publications

Subcutaneous device-free islet transplantation

Subcutaneous device-free islet transplantation

Pancreatic stellate cells support human pancreatic β-cell viability in vitro and enhance survival of immunoisolated human islets exposed to cytokines

Necrostatin‐1 releasing nanoparticles: In vitro and in vivo efficacy for supporting immunoisolated islet transplantation outcomes

Contact Info

Product

Resources

About